About us
Priscus Health and Tech (PHT) is a subsidiary of Priscus Finance, created at the end of 2022, which took over a seventeen-year expert business in the sector (vérifier)
PHT supports emerging bio-health companies, advising them on their strategy, financing and partnerships.
In addition to Priscus Finance, the partners are François GAUTHEY and Jean-Paul ROHMER.
Medtech
Health & Care
Discover the complete profile 
Infrastructure
Transport
Energy
Utilities
Technology start-ups
Biotech and medtech start-ups
Discover the complete profile
Insurance and brokerage
Discover the complete profile
Area covered
PHT supports companies in two sectors in particular:
- Start-ups developing diagnostic or analysis platforms (neurological diagnostics, cytometric analyses, for example) combining excellent mastery of Big Data and artificial intelligence with proven medical advances, leading to early sales.
- Biotechnology or biomedical start-ups developing a response to serious diseases for which there is no available treatment, based on breakthrough innovations that offer a real therapeutic innovation and have demonstrated their effectiveness in animal models.
These start-ups are generally positioned between two phases of development and valuation:
- a seed financing phase (F&F, initial public funding, business angels), during which the valuation is based on the funds invested,
- and a phase of financing by investment funds or large pharmaceutical groups with a valuation based on expected sales, with a sharp increase.
PHT is eager to help any young company in the bio-health sector with its development.
Examples of current projects
Alpha project
- Development of a treatment for haemorrhagic stroke using a new recombinant molecule.
- After having raised several seed capital rounds totalling almost €1m, PHT is now in the process of completing a €10m Series A financing round.
Beta project
- Development of a stem cell-based treatment for liver diseases.
- Following seed financing (€1m) supplemented by public funding, PHT is today launching a Series A financing round of around €8m.
Gamma project
- Development of early predictive diagnostics using a high-performance occulometry technique based on a unique database.
- PHT is helping to define an optimal strategy, including finding partners in the insurance sector, and raising between €5m and €10m.
Delta project
- Development of applications with a cutting-edge technology for assessing cellular metabolism, in diagnostics, laboratory techniques and the optimisation of cellular therapies.
- After raising 4 rounds of funding totalling €2.2m, PHT is structuring a €6-8m Series A.